Timothy P. Noyes - 29 Jun 2021 Form 3 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Chief Executive Officer, Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
29 Jun 2021
Net transactions value
$0
Form type
3
Filing time
29 Jun 2021, 19:42:20 UTC
Previous filing
01 Jul 2021
Next filing
16 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AVTE Stock Option (Right to Buy) 29 Jun 2021 Common Stock 254,253 $2.14 Direct F1
holding AVTE Stock Option (Right to Buy) 29 Jun 2021 Common Stock 493,381 $2.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on February 15, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F2 25% of this option shall vest and become exercisable on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney